Riluzole to Treat Depression in Bipolarity
Researchers are comparing Riluzole and placebo to find out how the approaches affect depression symptoms in people with bipolarity during a depressive episode.
Understand this study
What is this study about?
Researchers are comparing Riluzole and placebo to find out how the approaches affect depression symptoms in people with bipolarity during a depressive episode.
Who could participate?
This study is for people with bipolarity. Listed age limits: 18 years to 70 years. Other eligibility criteria apply.
- Listed locations
- BethesdaSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 19
- Sponsor
- National Institute of Mental Health (NIMH)
- Sponsor type
- Government agency
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT00054704
- Official title
Show the full official title
An Investigation of the Antidepressant Efficacy of an Antiglutamatergic Agent in Bipolar Depression
Recruitment & locations
Bethesda
Interested in joining this study?
Questions about this study
What is this study about?
Researchers are comparing Riluzole and placebo to find out how the approaches affect depression symptoms in people with bipolarity during a depressive episode.
Who is behind this study?
The study sponsor is National Institute of Mental Health (NIMH), a government agency.
Does this study involve medication?
Yes. The study involves medication, including Riluzole and Placebo.
Who can participate?
This study is for people with bipolarity. Listed age limits: 18 years to 70 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as terminated.
